GlassScriptPhysician profile
Jill R Hanson
NPI 1366763807
$15,488.81
in general payments reported to CMS, 2019-2025
30 companies · $4,853 in 2025
The $4,853 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,777 · 2020: $1,257 · 2021: $214 · 2022: $1,193 · 2023: $2,034 · 2024: $3,162 · 2025: $4,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,907 · Consulting Fee: $3,057 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,906.91 |
| Consulting Fee | $3,057.00 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,574.56 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $3,417.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,316.45 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $842.53 | 2022-2025 | Cuvitru, Hyqvia, Takhzyro |
| Abbvie INC. | $803.16 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $572.99 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $421.07 | 2019-2025 | |
| Genentech USA, INC. | $228.85 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $225.86 | 2020-2024 | |
| Inspire Medical Systems, INC. | $145.51 | 2024-2025 | Inspire |
| Amgen INC. | $134.95 | 2022-2023 | Tezspire |
| Grifols USA, LLC | $128.35 | 2022-2024 | Xembify, Prolastin-C Liquid |
| Csl Behring | $110.17 | 2024-2025 | Hizentra, Haegarda, Andembry |
| Kaleo, INC. | $108.94 | 2021-2024 | Auvi-Q |
| Pfizer INC. | $68.30 | 2023-2024 | Thrombin-Jmi, Gelfoam |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.47 | 2019-2021 | |
| Blueprint Medicines Corporation | $39.99 | 2024 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $36.84 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $36.24 | 2022 | |
| Biocryst US Sales Co., LLC | $34.00 | 2024 | Orladeyo |
| Sanofi Pasteur INC. | $28.28 | 2019 | |
| Aimmune Therapeutics, INC. | $25.54 | 2022 | |
| Optinose US, INC. | $22.91 | 2024 | |
| Organon LLC | $22.20 | 2025 | Vtama |
| Pharming Healthcare, INC. | $20.86 | 2025 | Ruconest |
| Hologic Sales and Service, LLC | $17.25 | 2024 | Coolseal Generator |
| Leo Pharma INC. | $15.01 | 2023 | Adbry |
| Coherus Oncology, INC. | $14.00 | 2024 | |
| Uswm, LLC | $13.32 | 2021 | |
| Boston Scientific Corporation | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.